Valproate is an anti-androgen and anti-progestin
- Publication Type:
- Journal Article
- Citation:
- Steroids, 2005, 70 (14), pp. 946 - 953
- Issue Date:
- 2005-12-15
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Anti-convulsant treatment is associated with a high prevalence of reproductive dysfunction compared with age-matched non-epileptics. We examined the widely used anti-convulsants valproate (VPA) and carbamazepine (CBZ) for steroidal bioactivity using a yeast-based steroid receptor-β-galactosidase reporter assay for the androgen receptor (AR), progesterone receptor (PR) or estrogen receptor (ER). Bioassays were performed (a) to detect agonist activity by exposing yeast to 100 μM CBZ or VPA or (b) to detect antagonist activity by exposing yeast stimulated with testosterone (5 × 10-9 M, AR), progesterone (1.6 × 10-9 M, PR) or estradiol (2.6 × 10-11 M, ER) together with either VPA or CBZ for 4 (PR) or 16 (AR, ER) hours. VPA showed dose-dependent (1-800 μM) inhibition of progesterone-induced PR- and testosterone-induced AR activity but had no ER antagonist bioactivity and no significant PR, AR or ER agonist bioactivity. VPA also showed a dose-dependent (1-200 μM) blockade of DHT's suppression of AR-mediated NF-κB activation in human mammalian cells. By contrast, CBZ had no significant PR, AR or ER agonist or AR and ER antagonist bioactivity but at the highest concentration tested (800 μM) it did antagonize PR activity. We conclude that VPA is a non-steroidal antagonist for human AR and PR but not ER. VPA's androgen and progesterone antagonism at concentrations within therapeutic blood levels (350-700 μM) seems likely to contribute to the frequency of reproductive endocrine disturbances among patients treated with VPA. © 2005 Elsevier Inc. All rights reserved.
Please use this identifier to cite or link to this item: